Alaunos Therapeutics, Inc. received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it…
Alaunos Therapeutics, Inc. (TCRT) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on April 9, 2026, Alaunos Therapeutics, Inc. (the “Company”) received a written notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in comp
- Exchange
- The Nasdaq Capital Market
- Kind
- regained compliance
- Rule
- Nasdaq Listing Rule 5550(b)(1)
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The removal of the delisting threat eliminates a binary downside catalyst, likely prompting short covering and modest buying.
Market read
The filing resolves a compliance issue that could have forced delisting, a material event for a micro‑cap stock, offering a short‑term trading opportunity.
What to watch
Potential upcoming financing needs or cash‑burn could re‑trigger equity shortfalls, keeping risk elevated.
Background
Nasdaq Capital Market requires a minimum of $2.5 million in stockholders' equity. Alaunos previously received a delisting notice and scheduled a hearing, which was later cancelled after the company proved compliance via a private placement.
Ticker impact
Alaunos Therapeutics disclosed that Nasdaq has closed its delisting hearing after confirming the company regained compliance with the $2.5M stockholders' equity requirement.
likely upward pressure as investors reassess the reduced compliance risk
The filing is the first public confirmation of regained compliance; market participants typically reward removal of a delisting threat.
Market effects
Minimal; primarily affects micro‑cap biotech/clinical‑stage companies that face similar equity‑listing thresholds.
Limited to U.S. Nasdaq‑listed microcaps.
Low; no broader macro or sector ripple.
Counterpoint
If the equity raise was dilutive or the company’s fundamentals remain weak, the price may not rally despite compliance.
Key entities
- companyAlaunos Therapeutics, Inc.
Biotech firm listed on Nasdaq (ticker TCRT) that faced a potential delisting.
- regulatory_bodyNasdaq Listing Qualifications Department
The Nasdaq staff that monitors compliance with listing standards.

